Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

ABVC BioPharma, Inc. ABVC

Healthcare  —  Biotechnology
1.13 0.04 3.67% as of 25 Sep
Market cap
$34.0M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

ABVC BioPharma, Inc. (ABVC) Business Profile

Updated before January 2025

Company Overview

ABVC BioPharma, Inc. (ABVC) is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapeutic solutions for unmet medical needs. Founded in 2015 and headquartered in Fremont, California, ABVC operates with a mission to improve patient outcomes through advanced drug development and medical technologies. The company is led by a team of seasoned professionals, including its CEO, Dr. Howard Doong, who brings extensive experience in the pharmaceutical and biotechnology sectors. ABVC’s leadership team is committed to driving innovation and fostering strategic partnerships to accelerate the development of its product pipeline.

Core Business Segments

ABVC focuses on two primary business segments: drug development and medical device innovation. These segments are supported by a robust pipeline of products and services aimed at addressing critical healthcare challenges.

Drug Development

ABVC’s drug development segment is centered on creating novel therapies for central nervous system (CNS) disorders, oncology, and other therapeutic areas. Key products under this category include:

  • ABV-1504: A promising treatment for major depressive disorder (MDD), currently in Phase II clinical trials.
  • ABV-1703: A potential therapy for non-small cell lung cancer (NSCLC), leveraging advanced immunotherapy techniques.
  • ABV-2002: A drug candidate targeting attention deficit hyperactivity disorder (ADHD) in pediatric populations.

Medical Device Innovation

In addition to pharmaceuticals, ABVC is actively involved in the development of cutting-edge medical devices. These devices aim to enhance diagnostic accuracy and improve patient care. Notable products include:

  • Vitargus®: A groundbreaking vitreous substitute for use in retinal detachment surgeries, designed to improve surgical outcomes and patient recovery.

Business Model

ABVC operates on a hybrid business model that integrates drug development and medical device innovation. The company generates revenue through licensing agreements, strategic partnerships, and milestone payments from collaborative research and development projects. By leveraging its proprietary technologies and intellectual property, ABVC aims to create a sustainable revenue stream while advancing its mission to address unmet medical needs.

Strategic Direction

ABVC’s strategic direction is focused on expanding its product pipeline, enhancing its global presence, and fostering collaborations with leading research institutions and pharmaceutical companies. Key initiatives include:

  • Pipeline Expansion: Accelerating the development of existing drug candidates and exploring new therapeutic areas.
  • Global Partnerships: Establishing strategic alliances to facilitate clinical trials, regulatory approvals, and market entry in key regions.
  • Sustainability Goals: Implementing environmentally friendly practices in research and manufacturing processes to minimize the company’s ecological footprint.

Competitive Landscape

ABVC operates in a highly competitive biopharmaceutical industry, facing competition from both established pharmaceutical giants and emerging biotech firms. Key competitors include:

  • Biogen Inc.: A leader in CNS therapies with a strong focus on neurological disorders.
  • Amgen Inc.: Known for its innovative oncology and immunology products.
  • Regeneron Pharmaceuticals: A major player in the development of biologics for various therapeutic areas.

Despite the competitive landscape, ABVC differentiates itself through its unique product offerings and commitment to addressing unmet medical needs.

Risk Factors

ABVC faces several risks that could impact its operations and financial performance, including:

  • Regulatory Challenges: Delays or failures in obtaining regulatory approvals for its drug candidates and medical devices.
  • Market Dependence: Heavy reliance on the success of a limited number of products in its pipeline.
  • Supply Chain Disruptions: Potential interruptions in the supply of raw materials and components for drug and device manufacturing.
  • Financial Constraints: The high costs associated with clinical trials and product development may strain the company’s financial resources.

Recent Developments

ABVC has made significant strides in advancing its product pipeline and strengthening its market position. Recent developments include:

  • Clinical Trial Progress: Successful completion of Phase II trials for ABV-1504, demonstrating promising efficacy and safety results.
  • Regulatory Milestones: Submission of a pre-market approval (PMA) application for Vitargus® to the U.S. Food and Drug Administration (FDA).
  • Strategic Partnerships: Collaboration with leading academic institutions to accelerate research and development efforts.

Global events, such as the COVID-19 pandemic, have also influenced ABVC’s operations, prompting the company to adopt remote work policies and prioritize the health and safety of its employees.

Investment Considerations

Investors considering ABVC should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: A diverse portfolio of drug candidates and medical devices targeting high-growth therapeutic areas.
  • Experienced Leadership: A management team with a proven track record in the biopharmaceutical industry.
  • Strategic Partnerships: Collaborations with reputable institutions and companies to enhance R&D capabilities.

Risks

  • High Development Costs: Significant financial resources required for clinical trials and regulatory approvals.
  • Market Competition: Intense competition from established players in the biopharmaceutical sector.
  • Regulatory Uncertainty: Potential delays or rejections in obtaining necessary approvals for product commercialization.

Conclusion

ABVC BioPharma, Inc. is well-positioned in the biopharmaceutical industry, with a strong focus on innovation and addressing unmet medical needs. While the company faces challenges such as regulatory hurdles and market competition, its robust pipeline, strategic partnerships, and experienced leadership provide a solid foundation for future growth. As ABVC continues to advance its product development efforts and expand its global presence, it remains an attractive investment opportunity for those seeking exposure to the biopharmaceutical sector.